ALSO NOTED: Impotence drug labels revised; Roche, GE to collaborate; Esprit buys rights to Sanctura; and much more...

> The FDA has approved revised labels for Levitra, Cialis and Viagra, warning users of a slight increase in the risk of sudden blindness. Story

> Roche and GE Healthcare will collaborate on upcoming tests of Roche's experimental Alzheimer's treatment. Report

> Esprit Pharma has acquired the US rights to Sanctura, a newly approved drug for overactive bladder. Report

> Abbott has struck a deal with the Brazilian government for its AIDS drug Kaletra. Story

> Canada's HepaLife Technologies has arranged up to $15 million in equity financing. Release

> Novartis has filed new applications to expand the use of Femara. Report

And Finally... The opening shot in what is widely expected to be a multibillion-dollar legal war over Merck's liability for Vioxx will get started this week in a small South Texas courtroom. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.